Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Your lung cancer has caused fluid to build up in the space around your lung. This fluid is
called a malignant pleural effusion. This fluid takes up space in your chest, and prevents
your lung from fully filling with air. As a result, you may be experiencing shortness of
breath, cough, or chest discomfort. Your doctors have determined that you would feel better
if a surgeon or pulmonary specialist removed this fluid immediately. Your doctors are
offering to admit you to the hospital, and drain the fluid using a Pleur-XTM catheter.
Once the Pleur-X catheter is in place, your doctors would like to start your chemotherapy.
Your doctors have decided to treat you with chemotherapy. If the chemotherapy works to kill
the cancer cells in your body, the cancer will make less fluid, and your doctors will be able
to remove the Pleur-XTM catheter sooner.
It is possible that adding a second drug to the chemotherapy, called bevacizumab may make he
fluid dry up even faster. It is not known whether adding bevacizumab to chemotherapy for
patients with a Pleur-XTM catheter in place is more helpful, or potentially more harmful,
than using chemotherapy alone. For this reason, only patients enrolled in this research
protocol can receive both chemotherapy and bevacizumab while they have a Pleur-XTM catheter
in place.
The purpose of this research study is to determine whether chemotherapy may be delivered
safely with a Pleur-XTM catheter in place.